GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Research & Development

MedMira (MedMira) Research & Development : $0.26 Mil (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. MedMira's Research & Development for the three months ended in Jan. 2024 was $0.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2024 was $0.26 Mil.


MedMira Research & Development Historical Data

The historical data trend for MedMira's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Research & Development Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.15 0.29 0.15 0.36

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.06 0.07 0.06

MedMira Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


MedMira Research & Development Related Terms

Thank you for viewing the detailed overview of MedMira's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports First Quarter Results FY2021

By GlobeNewswire GlobeNewswire 12-25-2020

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021